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Abstract
Background: Alzheimer’s disease (AD) is the most common neurodegenerative disease. In addition to the occurrence
of amyloid deposits and widespread tau pathology, AD is associated with a neuroinflammatory response characterized
by the activation of microglia and astrocytes. Protein kinase 2 (CK2, former casein kinase II) is involved in a wide variety
of cellular processes. Previous studies on CK2 in AD showed controversial results, and the involvement of CK2 in
neuroinflammation in AD remains elusive.
Methods: In this study, we used immunohistochemical and immunofluorescent staining methods to investigate the
localization of CK2 in the hippocampus and temporal cortex of patients with AD and non-demented controls. We
compared protein levels with Western blotting analysis, and we investigated CK2 activity in human U373 astrocytoma
cells and human primary adult astrocytes stimulated with IL-1β or TNF-α.
Results: We report increased levels of CK2 in the hippocampus and temporal cortex of AD patients compared
to non-demented controls. Immunohistochemical analysis shows CK2 immunoreactivity in astrocytes in AD and control
cases. In AD, the presence of CK2 immunoreactive astrocytes is increased. CK2 immunopositive astrocytes are associated
with amyloid deposits, suggesting an involvement of CK2 in the neuroinflammatory response. In U373 cells and human
primary astrocytes, the selective CK2 inhibitor CX-4945 shows a dose-dependent reduction of the IL-1β or TNF-α induced
MCP-1 and IL-6 secretion.
Conclusions: This data suggests that CK2 in astrocytes is involved in the neuroinflammatory response in AD.
The reduction in pro-inflammatory cytokine secretion by human astrocytes using the selective CK2 inhibitor
CX-4945 indicates that CK2 could be a potential target to modulate neuroinflammation in AD.
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Background
Alzheimer’s disease (AD) is currently the most common
neurodegenerative disease and is characterized by memory
loss and cognitive impairment. Pathological hallmarks of
AD include extracellular deposits of amyloid beta (Aβ), as
well as intracellular accumulations of hyperphosphorylated
tau in neurofibrillary tangles (NFTs) and neuropil threads
[1]. In approximately 80 % of AD cases, Aβ deposits are
also observed in parenchymal and leptomeningeal vessels,
which is referred to as cerebral amyloid angiopathy (CAA)
[2]. Two types of CAA can be distinguished: Aβ accumula-
tion in the walls of both larger vessels and capillaries (CAA
type I or capCAA) and Aβ accumulation only present in
the walls of larger vessels (CAA type II) [3]. It has been re-
ported that capCAA is associated with a neuroinflamma-
tory response resulting in alterations of the blood-brain
barrier (BBB) which contribute to AD pathology [2].
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In AD, neuroinflammation is associated with an in-
crease of activated complement proteins and cytokines,
such as interleukin 6 (IL-6) and monocyte chemotactic
protein-1 (MCP-1; also referred to as chemokine (C-C
motif ) ligand 2 (CCL2)), and activated microglia and as-
trocytes [4, 5]. Interestingly, these markers are already
present in the cerebral cortex at early stages of AD path-
ology [6–8]. Among the genes that increase the risk of
developing AD, several are associated with inflammation,
for instance TREM2, CD33, CR1 and CLU [9–14]. As
such inflammation is considered an integral part of AD
pathology [9, 10] and is characterized as a local activation
of the innate immune response, referred to as neuroin-
flammation. It is thought that the neuroinflammatory
response in AD is aimed at eliminating injurious stimuli
and restoring tissue integrity.
For the development of therapeutic strategies, it is
essential to elucidate the underlying processes and sig-
nalling pathways that drive AD pathology [15]. Protein
kinases are major targets for investigation as they are
involved in most cellular processes and are key regulators
of multiple signalling pathways [16]. In addition, many
protein kinases are drug-able and as such potential thera-
peutic targets for the treatment of AD [17].
One of the first protein kinases identified in an AD
brain was protein kinase CK2, formerly known as casein
kinase II [18, 19]. CK2 consists of two catalytic α sub-
units (39–45 kDa) and two regulatory β subunits
(26 kDa) and is constitutively active [20]. There are at
least three different isoforms for the catalytic α sub-
unit: α, α’ and α” [21, 22]. CK2 utilizes both adenosine
triphosphate (ATP) and guanosine triphosphate (GTP)
as phosphate donors [19, 23, 24] and has a broad
spectrum of over 300 protein substrates [23]. In addition
to phosphorylating serine and threonine residues, CK2 is
capable to phosphorylate tyrosine residues, thereby
making it a dual-specificity kinase [24, 25].
The mechanisms of CK2 regulation are poorly under-
stood. Emerging evidence suggests a potential role for
CK2 during pathogeneses associated with inflammation
[26]. CK2 regulates the activity of several key transcription
factors implicated in inflammation, e.g. nuclear factor
kappa-light-chain-enhancer in activated B cells (NF-κB)
[27]. In turn, an increasing number of studies report
the regulation of CK2 activity by cytokines and other
pro-inflammatory agents. Lipopolysaccharide (LPS) for
example, a major inducer of pro-inflammatory cytokine
expression, has been found to induce CK2 activity in
murine RAW264.7 macrophages [28]. Tumour necrosis
factor-α (TNF-α) has been shown to stimulate CK2 activ-
ity in Swiss L929, 3T3 and human cervical carcinoma
HeLa cells [26, 29, 30], and interleukin-1 (IL-1) has been
reported to activate CK2 in intestinal epithelial cells [31].
The transforming growth factor-β (TGF-β) has been
shown to stimulate CK2 activity in murine mesangial cells
and in macrophages [32, 33]. Furthermore, interferon-γ
(IFN-γ) induced CK2 activity in macrophages [34, 35]. Un-
derstanding the regulation of CK2 signalling and its role
in inflammatory pathways will be essential for the design
of novel therapeutic strategies for diseases associated with
inflammation such as AD.
A number of chemical compounds have been analysed
as inhibitors for CK2 [36, 37], like the ATP-competitive
4,5,6,7-tetrabromo-1H-benzotriazole (TBB) [38], which
has been used widely as a molecular probe to elucidate
the functional role of CK2. Another promising CK2 in-
hibitor is the small molecule CX-4945, also known as
Silmitasertib [39]. CX-4945 is a highly selective ATP-
competitive inhibitor of both CK2α and CK2α’ catalytic
subunits [39, 40]. It is orally administered and is cur-
rently the only CK2 inhibitor that is being evaluated in
clinical trials for the treatment of many cancer types
[40]. In phase I clinical trials for patients with different
solid tumours, adverse effects of CX-4945 were generally
mild to moderate, demonstrating that CX-4945 can be
safely administered to humans [41].
In this study, we have investigated the role of CK2 in
the hippocampus and temporal cortex of AD patients
and non-demented controls. In addition, we investigated
the effect of two CK2 inhibitors on IL-6 and MCP-1 se-
cretion in stimulated human primary astrocytes and
U373 cells. Our study provides support for a role of
CK2 in neuroinflammation suggesting that CK2 could
act as a potential target for modulating the inflamma-
tory response in AD.
Methods
Case selection
Brain samples were obtained from The Netherlands Brain
Bank (NBB), Netherlands Institute for Neuroscience
(Amsterdam, The Netherlands). All donors or their next
of kin gave written informed consent for a brain autopsy
and the use of the material and clinical information for re-
search purposes according to the Declaration of Helsinki.
This work was approved by the ethics committee of the
NBB. Dementia status at death was determined on the
basis of clinical information available during the last year
of life and neuropathological diagnosis using (immuno)-
histochemical stainings (haematoxylin and eosin, Bodian
and/or Gallyas silver stainings, methenamine silver
staining and immunohistochemial stainings for Aβ,
tau, α-synuclein, TDP and P62. Analysis of formalin-fixed
and paraffin-embedded tissue from different parts of the
brain was performed, including the frontal cortex (F2),
temporal pole cortex, parietal cortex (superior and inferior
lobule), occipital pole cortex, amygdala and the hippocam-
pus, essentially CA1 and entorhinal area of the parahippo-
campal gyrus. Staging of AD pathology was evaluated
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according to a modified assessment of Braak and Alafuzoff
[42] and the Aβ staging of Thal [43, 44]. Severity of de-
mentia was determined using the Global Deterioration
Scale of Reisberg (GDS) [45]. Cases with and without
clinical neurological disease diagnosis were processed
identically. Of all cases used for this study, age, sex,
clinical diagnosis, stage of AD pathology (Braak stage
and phase of Aβ deposition), CERAD score [46] and
post mortem delay (PMD) are listed in Table 1. We
compared non-demented cases with low AD pathology,
including seven cases of primary age-related tauopathy
(PART [47, 48]; Table 1: 4, 15, 17, 26, 27, 30, 31) and cases
with symptomatic, late-stage AD.
Preparation of brain tissue lysates
Twenty 10-μm-thick frozen tissue slices of the hippo-
campus and temporal cortex were cut at −20 °C. Brain
extracts were prepared by adding 100 mg wet-weight
brain tissue to 1 ml cold M-PER (Mammalian Protein
Extraction Reagent, Thermo Scientific, MA, USA) lysis
buffer containing Protease Inhibitor Cocktail (Roche, Ba-
sel, Switzerland) and Phosphatase Inhibitor Cocktail
(Roche). Samples were left on ice for 30 min and after
centrifugation (10 min, 4 °C, 10 000×g), the supernatant
was collected, snap frozen in 100 μl aliquots and stored
at −80 °C until further analysis. The protein concentra-
tion was determined using the Bradford Lowry Assay
(Bio-Rad Protein Assay, Hercules, CA, USA) with bovine
serum albumin (BSA, Roche) as standard.
Western blotting
Sample buffer (Thermo Scientific) was added to the pro-
tein lysates and heated for 5 min at 95 °C. Proteins were
separated by SDS-PAGE using a polyacrylamide gradient
gel in running buffer (25 mM Tris, 192 mM glycine,
0.1 % SDS, pH 8.3, Bio-Rad). In a separate experiment,
whole cell lysates of cultured primary astrocytes and
U373 cells were lysed with sample buffer in a 1:1 ratio
and heated for 5 min at 95 °C. Proteins were separated
on a custom cast acrylamide gel (10 %) and electrophor-
etically transferred onto a nitrocellulose membrane
(0.2 μm; Whatman, Protran™, Thermo Scientific) using
transfer buffer (25 mM Tris, 192 mM glycine, 20 %
methanol, Bio-Rad). Ponceau red S solution was used as
a loading control. Membranes were blocked for 1 h in
Tris-buffered saline (50 mM Tris pH 7.5, 0.15 M NaCl,
0.1 % Tween-20, pH 8.3) containing 5 % BSA (Roche)
and incubated over night with primary anti-CK2α anti-
body (1:500, mouse monoclonal, SC-12738, Santa Cruz
Biotechnology, CA). Subsequently, blots were incubated
with a secondary antibody linked to horseradish peroxidase
(HRP-anti-rabbit IgG or HRP-anti-mouse IgG, 1:1000,
Dako, Glostrup, Denmark) overnight at room temperature.
Immunoreactive bands were detected with an enhanced
chemiluminescence reagent (ECL Plus, GE Healthcare,
Buckinghamshire, UK). The intensity of the bands was
quantified using MacBiophotonics ImageJ (version 1.48k).
Data was expressed as relative signal intensities (CK2α/
Ponceau red S) of the individual samples. An overview of
the antibodies used in this study is given in Table 2. Recom-
binant CK2α and CK2α’ (100 ng; Millipore, Dundee, UK)
were used to determine the selectivity of the antibodies.
Immunohistochemistry
For immunohistochemical analysis, frozen 5-μm-thick
sections were mounted on coated glass slides (Menzel
Gläser Superfrost PLUS, Thermo Scientific). Sections were
fixed by immersion in acetone for 10 min, followed by
washing in phosphate-buffered saline (PBS, pH 7.4). Be-
tween the subsequent incubation steps, sections were
washed extensively with PBS. Incubation with the primary
antibodies was overnight at 4 °C. Mouse monoclonal anti-
GFAP (1:50, Monosan, Uden, The Netherlands), mouse
monoclonal anti-CK2α (1:50, Santa Cruz Biotechnology,
CA), mouse monoclonal anti-phospho-tau [49] (AT8 for
Tau pSer202 and pThr205, 1:800, Pierce Biotechnology)
and mouse monoclonal anti-Aβ (IC16 1:200, Prof. C.
Korth, Heinrich Heine University Düsseldorf, Germany)
were used. In addition, the mouse monoclonal anti-CK2α
antibody was tested on formalin-fixed, paraffin-embedded
tissue (Additional file 1: Figure S3). The antibodies
(Table 2) were diluted in antibody diluent (Immunologic,
Duiven, The Netherlands). Omission of the primary anti-
bodies served as a negative control. Secondary EnVison™
HRP goat anti-rabbit/mouse antibody (EV-GαMHRP, Dako)
incubation was for 30 min at room temperature. The sec-
ondary antibody was detected using 3,3-diaminobenzidine
(Dako). Sections were counterstained with haematoxylin
for 1 min to visualize the nuclei of the cells, dehydrated
and mounted using Quick-D mounting medium (BDH La-
boratories Supplies, Poole, England). For Congo red stain-
ing, sections were incubated with 50 ml saturated NaCl
solution (0.5 M NaCl in 80 % ethanol, supplemented with
0.5 ml 1 % NaOH) after dehydration. Sections were trans-
ferred to saturated 50 ml 0.5 % Congo red solution (VWR
International, Leuven, Belgium) for 20 min and mounted
with Quick-D mounting medium. CK2 immunoreactivity
was determined blinded to the pathological and clinical
diagnosis. Full images of six representative microscopic
fields were obtained using a Zeiss light microscope
equipped with a digital camera, a ×12 ocular and a ×10
objective. The percentage of the area showing immunore-
activity for a specific antibody (area fraction) was deter-
mined using MacBiophotonics Image-J software (version
1.48). Student’s t test was used to determine differences
between AD and CON cases. Results are expressed as
mean ± standard deviation (SD). A p value of <.05 was
considered significant.
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Localisation with triple immunofluorescence
To investigate co-localization of CK2, amyloid and as-
trocytes, frozen brain tissue sections were dried and
submerged in 100 % acetone for 10 min at room
temperature and subsequently incubated with thioflavin S
solution (100 mg/ml, Sigma, St. Louis, USA) for 5 min to
stain amyloid fibrils. The sections were washed with 100 %
ethanol and PBS, followed by incubation with Normal
Goat Serum (NGS, 1:10 dilution, Dako) for 10 min to
block a specific binding of the antibodies. Then, the sec-
tions were incubated with a mixture of primary antibodies:
CK2α (1:50, Santa Cruz Biotechnology) and GFAP (1:300,
Monosan) overnight at 4 °C. Subsequently, sections
were washed with PBS and incubated with a mixture of
Table 1 List of AD and CON cases used for this study














Sex Age PMD Pathological
diagnosis
1 0 O 0 M 51 7.45 CON
2 1 B 0 M 85 7.05 CON
3 1 A 0 F 60 7.30 CON
4 2 O 0 F 81 5.30 CON
5 3 A 0 F 91 5.20 CON
6 4 C 2 F 91 6.05 AD
7 5 C 2 F 89 4.40 AD
8 5 C 2 M 81 NA AD
9 5 B 2 F 69 7.10 AD
10 6 C 3 F 69 5.30 AD
11 6 C 3 F 68 3.50 AD
12 6 C 3 F 67 5.50 AD
B. Temporal cortex
13 0 B 0 M 74 7.45 CON
14 0 O 0 M 66 7.45 CON
15 1 O 0 M 77 8.25 CON
16 1 B 0 M 71 5.45 CON
17 2 O 0 F 93 5.50 CON
18 2 A 0 F 85 4.40 CON
19 3 C 1 F 82 6.05 AD
20 4 C 2 M 64 6.00 AD
21 5 C 3 F 71 4.15 AD
22 6 C 3 M 65 8.50 AD
23 6 C 3 F 64 3.40 AD
24 6 C 3 M 69 5.30 AD

















*25 0 O 0 M 74 8.05 CON
26 1 O 0 F 75 5.25 CON
27 1 O 0 M 82 5.50 CON
28 1 B 0 F 85 7.05 CON
29 1 B 0 F 73 7.45 CON
30 1 O 0 F 60 6.50 CON
31 1 O 0 M 78 17.40 CON
32 2 B 0 F 84 6.05 CON
33 2 B 0 F 83 4.40 CON
34 5 C 2 F 84 4.50 AD
35 6 C 3 F 62 4.45 AD
Table 1 List of AD and CON cases used for this study
(Continued)
*36 6 C 3 M 60 6.15 AD
37 6 C 3 F 82 5.30 AD
38 6 C 3 M 74 7.40 AD
39 6 C 3 F 81 6.00 AD
40 6 C 3 M 73 6.15 AD
41 6 C 3 M 74 5.35 AD
*42 6 C 3 F 82 6.00 AD
*43 6 C 3 F 67 6.05 AD
*44 5/6 NA NA M 76 24.00 AD, CAA
type 2
*45 5 C 3 M 65 7.20 AD, CAA
type 2
46 6 C 3 F 87 8.00 AD, CAA
type 2
CON control case, AD Alzheimer’s disease case, NFT neurofibrillary tangles,
CERAD consortium to establish a registry for Alzheimer’s disease, PMD post
mortem delay, hrs hours, CAA cerebral amyloid aniopathy, NA not available
All cases were used for quantification (Figs. 1 and 3) except when indicated with *
Table 2 Overview of antibodies




CK2α Mouse 1:500 Santa Cruz Biotechnology, CA,
USA
CK2α' Goat 1:500 Santa Cruz Biotechnology, CA,
USA
HRP anti-mouse Rabbit 1:1000 Dako, Glostrup, Denmark
HRP anti-goat Rabbit 1:1000 Dako, Glostrup, Denmark
Antibodies used for immunohistochemistry
Tau pSer202,
pThr205 (AT8)
Mouse 1:800 Pierce, Rockford, IL, USA
Aβ (IC-16) Mouse 1:200 Prof. C. Korth, Düsseldorf,
Germany
GFAP Mouse 1:50 Monosan, Uden, The Netherlands
CK2α Mouse 1:50 Santa Cruz Biotechnology, CA, USA
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secondary antibodies: EV-GαMHRP (Dako) and GαR-Cy5
(1:100, Jackson ImmunoResearch Laboratories, West
Grove, PA) for 1 h. The sections were washed with PBS
and developed with rhodamine/tyramide intensification
(1:3000, 0.01 % H2O2) for 5 min. To block autofluores-
cence, the sections were incubated with Sudan Black
(0.3 %, diluted in 70 % ethanol). Sections were mounted in
plain 80 % Tris-buffered glycerol.
In vitro functional assays
Adult primary human astrocytes were isolated from brain
specimens obtained at autopsy through The Netherlands
Brain Bank and cultured as described previously [50, 51].
Primary astrocyte cultures from clinically diagnosed AD
patients and control cases (patients with epilepsy) were
included in this study. No differences in functionality
were observed between the astrocytes from different
cases. All experiments were performed at least in triplicates.
The human glioblastoma cell line U373 (HTB-17) was ob-
tained from American Type Culture Collection (ATCC,
Rockville, MD, USA). Cells were grown at 37 °C as a mono-
layer in culture medium (Dulbecco’s modified Eagle’s
medium (DMEM) and Ham’s F10 Nutrient Mixture
(HAM-F10) 1:1, supplemented with 2 mM L-glutamin
(Gibco, Waltham, MA, USA), 10 % (v/v) foetal calf serum
(FCS, Integro, Zaandam, The Netherlands), 100 U/ml
penicillin (Gibco) and 50 μg/ml streptomycin (Gibco) with
5 % CO2 in culture flasks (Greiner, Alphen a/d Rijn, The
Netherlands)).
For stimulation/inhibition experiments, U373 cells
and primary astrocytes were trypsinized (Sigma) and
transferred to 24-well plate (Nunc, Roskilde, Denmark) at
5 × 104 cells/well in culture medium. Stock solutions of the
inhibitors tetrabromobenzotriazole (64 mM, TBB, Sigma)
and 5-(3-chlorophenylamino)benzo[c][2,6]-naphthyridine-
8-carboxylic acid (CX-4945, 100 mM, Medchem, Leiden,
The Netherlands) were prepared in dimethylsulfoxide
(DMSO, Merck, Kenilworth, NJ, USA). The inhibitor was
added to the cultures 1 h prior to co-incubation with either
human recombinant IL-1β (10 U/ml, Peprotech, London,
UK) or TNF-α (100 ng/ml, Immuno Tools, Friesoythe,
Germany) for 24 h in culture medium containing 10 %
foetal bovine serum (FCS). IL-1β/TNF-α was added directly
onto the culture medium which contained the inhibitor.
The final DMSO concentration never exceeded 0.03 % for
TBB and 0.01 % for CX-4945. Cell culture medium was col-
lected by centrifugation and stored at −20 °C until further
analysis. The monocyte chemoattractant protein-1 (MCP-
1) was determined using the DuoSet MCP-1 enzyme-linked
immune sorbent assay (ELISA) (R&D Systems Europe,
Abingdon, UK), while for interleukin-6 (IL-6), the Pelipair
IL-6 ELISA kit (Sanquin, Amsterdam, The Netherlands)
was employed. The effect of TBB and CX-4945 inhibi-
tor on cell viability was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT/Formazan) assay [52]. For statistical analysis,
unpaired t tests were performed.
Fluorescent immunocytochemistry of cultured cells
Primary astrocytes and U373 cells were stimulated as de-
scribed in 2.6 and cultured on a borosilicate glass slide
(VWR International, Amsterdam, The Netherlands) in a
24-well plate. After 24 h, culture medium was collected
and the glass slides with the cells were washed with PBS.
After fixation in 4 % formaldehyde (Klinipath, Duiven,
The Netherlands) for 15 min, cells were washed with
PBS 0.1 % Triton (Merck) for 30 min. Cells were incu-
bated with the CK2α antibody (Santa Cruz, 1:50 dilution
in PBS 0.05 % Triton/0.5 % BSA) overnight at room
temperature while shaking. After washing for three times
with 500 μl PBS/0.1 % Triton, the cells were incubated
with the secondary fluorescently labelled antibody (Alexa
fluor 594, Invitrogen) in a dilution of 1:1000 for 90 min
in a dark environment on a shaker. After washing with
PBS, cell nuclei were stained with DAPI (1:10.000 di-
lution in PBS, Life Technologies, Amsterdam, The
Netherlands) for 10 min. The cells were washed with
PBS and transferred to a microscopy slide (Menzel,
superfrost colour, Thermo Scientific) using an 80 %
Tris-HCl buffered glycerol solution (pH 7.5).
Results
CK2 protein levels are increased in AD brain
CK2 protein levels were assessed by Western blot ana-
lysis using brain tissue extracts of the temporal cortex
and hippocampus of AD and non-demented control
cases (CON; Table 1). Recombinant human CK2α and
CK2α’ proteins were used to determine the specificity of
the antibodies. Mouse monoclonal anti-CK2α detected
the α-isoform as well as the α’-isoform (indicated by
CK2α/α’ throughout the manuscript), whereas the goat
polyclonal anti-CK2α’ only detected the α’-isoform
(Additional file 2: Figure S1). In protein lysates obtained
from post mortem human hippocampus (Fig. 1a) and
temporal cortex (Fig. 1b), four bands between 37 and
50 kDa were detected using the CK2α/α’ antibody. Based
on bands obtained with the recombinant proteins, the
second and third band observed with the brain extracts
were assigned to CK2α and CK2α’, respectively. It is
likely that the other two bands correspond to different
isoforms of CK2 [21]. Increased levels of CK2α/α’ com-
pared to controls were observed in the hippocampus
(Fig. 1c) and temporal cortex (Fig. 1d) of AD brains. In
the hippocampus, increased levels of CK2 became appar-
ent at Braak stage 4 (Fig. 1a), while in the temporal cor-
tex, a prominent increase was observed in Braak stage 6
(Fig. 1b). The full Western blots are shown in Additional
file 3: Figure S2.
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CK2α/α’ immunoreactivity is increased in AD patients and
is associated with astrocytes, amyloid fibrils and blood
vessels
The localization and distribution of CK2 in the temporal
cortex and hippocampus of AD and control cases was
assessed using immunohistochemistry on fresh-frozen
tissue. Representative images are shown in Fig. 2. Similar
results were obtained with CK2 immunohistochemistry
on formalin-fixed paraffin-embedded brain tissue
(Additional file 1: Figure S3). CK2α/α’ staining showed a
star-like shape and was found in both control and AD
cases. Based on the morphological appearance, immuno-
reactive cells could be identified as astrocytes. In control
cases, CK2α/α’ immunoreactivity was specifically observed
in the grey matter of the mid-temporal cortex (Fig. 2a and
b) around blood vessels (Fig. 2c) and in the white matter
(Fig. 2d and e) and was less prominent in the hippocampal
CA1 area (Fig. 2f). There was no difference between the
CK2α/α’ levels in the white matter of AD cases (Fig. 2j, k)
and controls. In contrast, CK2α/α’ immunoreactivity
was increased in AD, prominently in the grey matter
regions of the temporal cortex (Fig. 2g). The CK2α/α’
immunoreactivity in the temporal cortex of 16 patients
(8 control and 8 AD cases; Table 1) was determined
and quantified. A significant increase of CK2α/α’ in AD
brains compared to controls (p value <.05; Fig. 3) was
observed. An increase of CK2α/α’ in AD compared to
control was also detected in the CA1 region of the hippo-
campus (Fig. 2f, l). Interestingly, CK2α/α’ immunoreactiv-
ity in the cortical areas showed a clustered distribution
(Fig. 2h, i), which might suggest the presence of amyloid
depositions.
To confirm the increased appearance of CK2α/α’ im-
munoreactivity around amyloid deposits, we performed
co-stainings of CK2α/α’ with different amyloid dyes. In-
creased CK2α/α’ immunoreactivity was observed around
Congo red positive amyloid plaques (Fig. 4a). In addition,
CK2α/α’ immunoreactivity was also associated with differ-
ent types of cerebral amyloid angiopathy, with large blood
vessels containing amyloid (Fig. 4b) as well as amyloid
containing capillaries (Fig. 4c). CK2α/α’ immunoreactivity
was also observed around Thioflavin S positive amyloid
plaques in AD temporal cortex and hippocampus (Fig. 5).
To confirm that CK2α/α’ immunoreactive cells were































































Fig. 1 Expression of CK2 in the hippocampus and temporal cortex. Protein expression of CK2 was assessed by Western blot analysis using mouse
anti-CK2 which detects both CK2α and CK2α’ (see Additional file 2: Figure S1). a Western blot analysis of brain extracts from the hippocampus.
b Western blot analysis of brain extracts from the temporal cortex. AD and non-demented control (CON) cases analysed by Western blotting are
listed in Table 1. Braak stages are indicated, and recombinant CK2α and CK2α’ were used as positive controls. Ponceau red staining was used in
order to determine the relative protein load on the blotting membrane. c Quantification of CK2α/α’ expression in the hippocampus of AD and
control cases. d Quantification of CK2α/α’ protein expression in the temporal cortex. Shown are mean levels +/− SD
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indeed astrocytes, co-labelling was performed with the
astrocytic marker GFAP. This indicates that CK2α/α’
co-localizes with astrocytes present around amyloid
deposits in the hippocampus and temporal cortex of
AD patients (Fig. 5).
CK2 activity in human primary astrocytes and U373 cells
is inhibited by CX-4945
Since CK2 primarily co-localizes with astrocytes (Fig. 5),
CK2 activity was assessed in adult human primary as-
trocytes and in the astrocytoma cell line U373 to
investigate the role of CK2 in neuroinflammation.
Two ATP-competitive inhibitors were chosen for
functional analysis of CK2 activity, namely TBB, one
of the most studied CK2 inhibitors [53] and the highly
selective CK2 inhibitor CX-4945. The MTT assay
showed that the mitochondrial activity, which was used
as a marker for cell viability, was not affected in the pres-
ence of either TBB or CX-4945 in concentrations up to 20
and 10 μM, respectively (data not shown). Since we ob-
served prominent presence of CK2 in reactive astrocytes


















Fig. 2 Immunohistochemical detection of CK2α/α’ in control and AD brain. Shown are representative immunohistochemical stainings for CK2α/α’
of the mid-temporal cortex and hippocampus of a control (a–f, Braak stage 0, Table 1C case #25) and two AD cases (Braak stage VI, Table 1C cases
g–i #35 and j–l #36). a CK2α/α’ immunoreactivity in the grey matter of the mid-temporal cortex in a control case. b CK2α/α’ immunoreactivity in the
subpial layer of the mid-temporal cortex in a control cases. c Detailed picture of CK2α/α’ immunoreactivity in astrocytes around a blood vessel in the
grey matter of the mid-temporal cortex in a control case. d Overview of CK2α/α’ immunoreactivity in astrocytes in the white matter (temporal cortex)
of a control case. e Detailed picture of CK2α/α’ immunoreactivity in the white matter of a control case. f CK2α/α’ immunoreactivity in the CA1 region
of the hippocampus of a control case. g CK2α/α’ immunoreactivity in the grey matter of the mid-temporal cortex in an AD case. h, i Detailed
pictures of clusters of astrocytes with CK2α/α’ immunoreactivity in the grey matter of the mid-temporal cortex in an AD case. j Overview of
CK2α/α’ immunoreactivity in the white matter (temporal cortex) of an AD case. k Detailed picture of CK2α/α’ immunoreactivity in astrocytes
in the white matter of an AD case. l CK2α/α’ immunoreactivity in the CA1 region of the hippocampus of an AD case. Immunohistochemical
detection was performed using DAB (brown) and nuclei were stained with haematoxylin (blue). Scale bars a, b, d, g and j 200 μm; f and l
100 μm; c, e, h, i and k 50 μm
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inflammatory model resembling the situation around
the amyloid deposits [54, 55]. U373 cells and human as-
trocytes were stimulated with IL-1β or TNF-α, which in-
duced the secretion of MCP-1 and IL-6 (Fig. 6).
The stimulation of U373 cells with IL-1β (24 h) in the
presence of CX-4945 resulted in a significant decrease of
the levels of IL-6 in the culture supernatant, i.e. to 50 %
at 5 μM and 25 % at 10 μM of inhibitor concentration
(Fig. 6a). The TNF-α stimulated U373 cells (24 h) were
slightly more responsive to inhibition compared to IL-1β
stimulated cells. The amount of IL-6 in the medium was
reduced to 40 % at 5 μM (Fig. 6a). The amount of secreted
MCP-1 by U373 cells was decreased in the presence of
CX-4945 to 80 % at a concentration of 1 μM, both for
IL-1β and TNF-α stimulated cells (Fig. 6c).
Similar results were obtained with human primary astro-
cytes. We observed a significant decrease of IL-6 in the cul-
ture supernatant of stimulated astrocytes in the presence of
10 μM CX-4945, i.e. to 45 % for IL-1β-stimulated astrocytes
and for TNF-α-stimulated astrocytes, a decrease to 50 %
(Fig. 6b). The MCP-1 secretion was effected more upon
treatment with CX-4945 compared to IL-6 secretion in the
culture supernatant. For IL-1β stimulated astrocytes, the
amount of MCP-1 was reduced to 40 and 25 % in the pres-
ence of 5 and 10 μM CX-4945, respectively (Fig. 6d). For
TNF-α stimulated astrocytes, a decrease to 50 and 40 % of
MCP-1 was observed in the presence of 5 and 10 μM CX-
4945, respectively. No significant reduction of IL-6 and
MCP-1 levels in the culture supernatant of stimulated
U373 cells of human primary astrocytes was observed after
incubation with TBB (Fig. 6e-h).
In order to investigate if the observed changes oc-


























Fig. 3 Quantification of CK2α/α’ immunoreactivity in the temporal
cortex of CON and AD patients. Quantification of CK2α/α’ positivity
in the temporal cortex (grey matter) of AD patients (n = 8) and
non-demented controls (CON, n = 8). Mean levels (± SD) of the
area density are expressed as percentage of immunoreactive area




Fig. 4 Association of CK2α/α’ with amyloid deposits in AD.
Representative pictures are shown of combined Congo red and
immunohistochemical stainings for CK2α/α’ of the cortex of two AD cases
(a: Braak stage V, Table 1C case #45; b+ c: Braak stage V/VI, Table 1C
case #44). a Association of astrocytes immunoreactive for CK2α/α’ with a
Congo red positive amyloid plaque. b Astrocytes immunoreactive for
CK2α/α’ associated with a Congo red positive blood vessel. c Association
of CK2α/α’ immunoreactivity with a Congo red positive capillary.
Immunohistochemical detection was performed using DAB (brown) and
nuclei were stained with haematoxylin (blue). Scale bar A-C 100 μm
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activity or the protein level of CK2α/α’, Western blotting
analysis was performed with primary human astrocytes
and U373 cells. Using the monoclonal mouse antibody
detecting both CK2α and CK2α’, we were not able to de-
tect CK2 by Western blotting or immunofluorescence of
cultured cells. No changes in protein levels of CK2α’
were observed upon stimulation of primary astrocytes
(Fig. 7a) or U373 cells (Fig. 7b) stimulated with IL-1β or
TNF-α, nor in the presence of CX-4945. Furthermore,
the cellular localization of CK2α’ in both cytoplasm and
the cell nuclei [56, 57] as well as protein levels of CK2α’
in primary astrocytes remained unchanged after stimula-
tion with either IL-1β or TNF-α (Fig. 7c). The same ob-
servations were made with the U373 cells (data not
shown). We conclude that CK2 activity rather than ex-
pression is involved in modulating the IL-1β or TNF-α
induced MCP-1 and IL-6 secretion.
Discussion
In this study, we report that the amount of CK2α/α’ is
increased in hippocampus and temporal cortex of AD
patients. CK2α/α’ co-localizes with astrocytes, and, in
AD cases, CK2α/α’ immunoreactive astrocytes surround
amyloid deposits. The selective CK2 inhibitor CX-4945
reduces the IL-1β or TNF-α induced secretion of MCP-
1 and IL-6 both in human primary astrocytes and U373
cells in a dose-dependent manner without affecting the
protein expression levels of CK2α’.
CK2 has been suggested to potentially play different
roles in AD, during synaptic plasticity [58, 59], APP
processing [60–62], tau accumulation [63, 64] and insulin
signalling [65]. There are contradictory reports on the
expression levels of CK2 observed in AD brain tissue.
Decreased CK2 activity has been reported in the frontal
cortex of AD patients [18, 66, 67]. In contrast, in-
creased CK2 expression, preceding tau accumulation
and tangle formation, has been observed during human
AD pathogenesis [68]. Initial studies reported that CK2 is
expressed in neurons [56, 57]. More recently, Kramerov et
al. showed that CK2 is expressed in astroglial cells of nor-
mal and neovascularized retina, thereby suggesting that
CK2 might be useful as a new immunohistochemical
marker for astrocytes [69, 70].
To study the involvement of CK2 in AD pathology, we
compared symptomatic, late-stage AD cases (Braak V +VI)
with non-demented and pre-clinical AD cases (Braak 0–II),
including cases of PART. CK2 levels showed a prominent
increase with Braak stage. We were able to confirm the
results of Kramerov et al. and show that CK2 is present
in astrocytes in AD and control temporal cortex and
hippocampal brain tissue. Previous reports have shown
that astrocytes are involved at early stages of AD pathology,
for example, the uptake and removal of Aβ [71, 72] and that
the inflammatory response is a driving factor in AD path-
ology. Our data suggests a role for CK2 in astrocyte func-
tion during the neuroinflammatory response in AD. We
show that inhibition of CK2 reduces part of the inflamma-
tory response driven by astrocytes. Whether CK2 is func-
tionally involved in early phases of Aβ pathology remains
elusive and should be investigated in future studies.
A B C D
E F G H
CK2 / fibrils              GFAP                          merged 
Fig. 5 Triple fluorescent stainings of CK2α/α’, amyloid fibrils and astrocytes in temporal cortex and hippocampus of AD patients. Shown are
representative immunohistochemical stainings for CK2α/α’ of the mid-temporal cortex (a–d, Braak stage VI, Table 1C case #43) and hippocampus
(e–h, Braak stage VI, Table 1C case #42) of two AD patients. a, e CK2α/α’ immunoreactivity, b, f amyloid fibrils (Thioflavin) and c, g astrocytes
(GFAP) in the temporal cortex (a–d, Braak stage VI, Table 1C case #43) and hippocampus (e–h, Braak stage VI, Table 1C case #42) of AD patients.
Immunofluorescent detection was performed using CKα/α’ (red), amyloid fibrils (green) and astrocytes (GFAP) (blue). Scale bars A–H 50 μm
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Aberrant CK2 signalling has been implicated in several
inflammatory diseases such as T cell lymphoma [73],
breast cancer [26, 74, 75] and autoimmune encephalo-
myelitis [76]. CK2 is known to mediate the regulation of
key transcription factors and cytokines such as serum
IL-6 and the signal transducer and activator of transcription
3 (STAT3) [74] and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB). The mechanism
of NF-κB regulation by CK2 has been well-studied in
epithelial cells [26, 31] and in cell models such as hu-
man cancerous HeLa cells [77] and diploid gingival fi-
broblasts [26, 27]. In turn, TNF-α has been shown to
stimulate CK2 activity in Swiss 3T3, L929 and human





















































A U373 cells B Primary astrocytes
C U373 cells D Primary astrocytes
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E U373 cells F Primary astrocytes
G U373 cells H Primary astrocytes
Unstimulated            IL-1 TNF-
TBB         0 1   5  20       0 1   5   20      0 1   5  20
Unstimulated            IL-1 TNF-
TBB         0    1   5  20       0 1   5   20      0 1   5  20
Unstimulated            IL-1 TNF-
TBB         0    1   5  20       0 1   5   20      0   1   5  20
Unstimulated            IL-1 TNF-
TBB         0    1   5  20       0 1   5   20       0 1   5  20
Fig. 6 Effect of CK2 inhibitors on IL-6 and MCP-1 secretion. U373 cells and human primary astrocytes were stimulated with either IL-1β (10 U/ml)
or TNF-α (100 ng/ml) for 24 h in the absence or presence of different concentrations of CX-4945 (a) or TBB (b). IL-6 and MCP-1 levels in the culture
supernatants were determined by ELISA. The stars indicate significant difference (p value <.05) between the condition without inhibitor, labelled with
0 μM, and the corresponding condition with either 1, 5 or 10 μM CX-4945 (a–d) or 1, 5, 20 μM TBB (e–h)
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been found to activate CK2 in intestinal epithelial cells
[31]. In addition to increased presence of CK2 positive
astrocytes around amyloid plaques, we observed in-
creased presence of CK2 positive astrocytes associated
with CAA in AD. The chronically increased production
of inflammatory cytokines is one of the causes of
blood-brain barrier (BBB) dysfunction [5, 78]. This sug-
gests that CK2 could be involved in the inflammatory
driven dysfunction of the BBB observed in AD.
The ATP-competitive CK2 inhibitor TBB has been used
widely as a molecular probe to elucidate the functional
role of CK2 [38]. In this study, we report that TBB had no
significant effect on the IL-1β/TNF-α mediated secretion
of IL-6 and MCP-1 by human primary astrocytes and
U373 cells. Previously, Kramerov et al. reported a minimal
effective concentration of 75 μM TBB for retinal
astrocytes in culture [69]. In the current study, we tested
concentrations up to 20 μM due to decline of cell viability
when using higher concentrations.
The selective CK2 inhibitor CX-4945 on the other
hand led to significant inhibition of the IL-1β/TNF-α
mediated secretion of IL-6 and MCP-1 by human pri-
mary astrocytes and U373 cells. CK2 overexpression has
been implicated in a number of different cancers includ-
ing head and neck [79], colorectal [80], renal [81], lung
[82], leukemias [83] and prostate cancer [84]. It has been
reported that angiogenesis and proliferation are regu-
lated by CK2 and that CK2 is an essential protein for
cancer cell survival [85]. Downregulation of CK2 activity
with specific inhibitors, like CX-4945, could reduce can-
cer cell viability and induce apoptosis [40, 74]. CX-4945
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unstimulated           IL-1 TNF-C
unstimulated                        IL-1 TNF-
Fig. 7 CK2α’ expression levels in primary astrocytes after stimulation with IL-1β or TNF-α in the presence of CX-4945. a Astrocytes were immunostained
for CK2 (goat anti-CK2α’ antibody) in red (Alexa 594) without stimulation and after stimulation with IL-1β or TNF-α. Scale bar for all panels
50 μm. b CK2α’ expression levels were determined by Western blotting (goat anti-CK2α’ antibody). Human primary astrocytes or c U373 cells
were cultured without stimulus, with IL-1β or TNF- α for 24 h in the absence or presence of CX-4945 (1–10 μM)
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downregulates signalling cascades that act downstream of
BCR, including PI3K/Akt/mTOR signalling by directly
blocking the phosphorylation of Akt at Serine 129 by CK2
[40, 85]. CX-4945 is currently the only CK2 inhibitor used
in clinical trials for cancer therapy [39, 40]. In phase I clin-
ical trials for patients with different solid tumours, adverse
effects of CX-4945 were generally mild to moderate, dem-
onstrating that CX-4945 can be safely administered to
humans [41, 85-86]. Chon et al. reported that CX-4945 in
combination with other inhibitors yielded synergistic ef-
fects in cell death induction making this inhibitor a
promising therapeutic tool for the treatment of cancer
and possibly other inflammatory diseases such as AD
[40].
Overall, our data suggests a role for protein kinase
CK2 in the neuroinflammatory response in AD. Although
neuroinflammation in the brain of AD patients is consid-
ered primarily beneficial, i.e. removing Aβ aggregates from
the brain, a chronic neuroinflammatory response is thought
to be harmful due to the constant excess production of
pro-inflammatory cytokines, prostaglandins and reactive
oxygen species that exacerbate Aβ deposition and induce
neuronal dysfunction [87]. However, all clinical trials with
AD patients using anti-inflammatory drugs have failed so
far, indicating the need for new anti-inflammatory
treatments [88]. Protein kinases can be targeted by
relatively small compounds that are able to pass the
BBB [17]. Therefore, the regulation of protein kinase
activity by small ligand molecules seems very promising
for future drug-based therapy directed at inflammation or
neurodegeneration. The anti-inflammatory effects of CX-
4945 on human astrocytes suggest that the CK2 signalling
pathway could act as a potential therapeutic target for
modulating neuroinflammation in AD. Whether CX-4945
is able to pass the BBB in order to reduce neuroinflamma-
tion in the brain needs to be resolved.
Conclusions
In conclusion, we found that CK2α/α’ is increased in as-
trocytes in the hippocampus and temporal cortex of AD
patients. CK2α/α’ immunoreactive astrocytes are associ-
ated with amyloid deposits in AD brain. The selective
CK2 inhibitor CX-4945 significantly reduced the IL-1β/
TNF-α induced secretion of the inflammatory cytokines
MCP-1 and IL-6 both in human primary astrocytes and
U373 astrocytoma cells in a dose-dependent manner.
This suggests that CK2α/α’ is a modulator of neuroin-
flammation in AD.
Additional files
Additional file 1: Figure S3. Detection of CK2α/α’ on formalin fixed
paraffin embedded tissue. Five-micrometer-thick sections from formalin-
fixed paraffin tissue were mounted on superfrost plus tissue slides
(Menzel-Gläser, Germany) and dried overnight at 37 °C. Sections were
deparaffinised and subsequently immersed in 0.3 % H2O2 in methanol
for 30 min to quench endogenous peroxidase activity. Between the
subsequent incubation steps, sections were washed extensively with
PBS. Sections were treated in 10 mM pH 6.0 sodium citrate buffer heated by
autoclave during 10 min for antigen retrieval. Mouse monoclonal anti-CK2α
(1:100, Santa Cruz Biotechnology, CA) was diluted in antibody diluent
(Immunologic) and incubated overnight at 4 °C. Omission of the primary
antibody served as a negative control. Secondary EnVisonTM HRP goat
anti-rabbit/mouse antibody (EV-GαMHRP, Dako) incubation was for 30 min
at 4 °C. The secondary antibody was detected using 3,3-diaminobenzidine
(Dako). Sections were counterstained with haematoxylin for 1 min,
dehydrated and mounted using Quick-D mounting medium (BDH
Laboratories Supplies, Poole, England). Shown are representative pictures
from the temporal cortex of an AD case with Braak 6 for neurofibrillary
tangles. Scale bar A 200 μm, B 50 μm. (PDF 208 kb)
Additional file 2: Figure S1. Specificity of CK2α and CK2α’ antibodies.
Western blot analysis of recombinant CK2α and CK2α’ in three different
concentrations. Incubation with either mouse anti-CK2α or goat anti-CK2α’
goat antibody using a 1:1000 dilution was performed overnight. (PDF 104 kb)
Additional file 3: Figure S2. Expression of CK2 in the hippocampus
and temporal cortex. Protein expression of CK2 was assessed by Western
blot analysis using mouse anti-CK2 which detects both CK2α and CK2α’
(see Additional file 2: Figure S1). a Western blot analysis of brain extracts
from the hippocampus. b Western blot analysis of brain extracts from the
temporal cortex. AD and non-demented control (CON) cases analysed by
Western blotting are listed in (Table 1). Braak stages are indicated, and re-
combinant CK2α and CK2α’ were used as positive controls. (PDF 137 kb)
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